Agabiti-Rosei E, Alicandri C L, Beschi M, Castellano M, Fariello R, Montini E, Muiesan M L, Romanelli G, Muiesan G
Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):87S-92S. doi: 10.1111/j.1365-2125.1982.tb01894.x.
1 Labetalol 100 mg was given intravenously to 27 patients with essential hypertension (12 males, 15 females; WHO I-II; age range 30-66 yr; on average, a significant reduction of blood pressure was observed within 5 min (P less than 0.001). Average heart rate was also reduced significantly (P less than 0.01). 2 In 18 patients haemodynamic measurements were performed (dye-dilution or thermodilution technique): blood pressure reduction was related to peripheral vasodilatation, as cardiac index remained unmodified. 3 The absolute and percentage decrease of blood pressure, heart rate and total peripheral resistance after labetalol 100 mg intravenously, was significantly greater in the patients with higher baseline plasma noradrenaline concentration values. 4 In 12 out of 27 patients labetalol was given orally for 2 months (dose range 300-1200 mg); the pattern of blood pressure and heart rate changes after oral therapy were comparable to those observed after acute administration of the drug. 5 The degree of blood pressure and heart rate reductions after oral labetalol was also significantly related to pretreatment basal noradrenaline concentration.
对27例原发性高血压患者(12例男性,15例女性;WHO I-II级;年龄范围30 - 66岁)静脉注射100毫克拉贝洛尔,5分钟内观察到血压显著降低(P<0.001)。平均心率也显著降低(P<0.01)。
对18例患者进行了血流动力学测量(染料稀释或热稀释技术):血压降低与外周血管扩张有关,因为心脏指数未改变。
静脉注射100毫克拉贝洛尔后,基线血浆去甲肾上腺素浓度值较高的患者,其血压、心率和总外周阻力的绝对下降和百分比下降显著更大。
27例患者中有12例口服拉贝洛尔2个月(剂量范围300 - 1200毫克);口服治疗后血压和心率变化模式与药物急性给药后观察到的相似。
口服拉贝洛尔后血压和心率降低的程度也与治疗前基础去甲肾上腺素浓度显著相关。